TN2011000379A1 - [1, 2, 4] triazolo [1,5-a ] pyridines as kinase inhibitors - Google Patents

[1, 2, 4] triazolo [1,5-a ] pyridines as kinase inhibitors

Info

Publication number: TN2011000379A1
Authority: TN; Tunisia
Prior art keywords: methods; kinase; diseases; ameliorating; treating
Prior art date: 2009-02-13

Application number

TN2011000379A

Other languages

English (en)

Inventor

Caroline Leriche

Eric Auclair

Roux Jacques Le

David Middlemiss

Original Assignee

Fovea Pharmaceuticals

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-13

Filing date

2011-08-03

Publication date

2013-03-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42229029&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000379(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-08-03 Application filed by Fovea Pharmaceuticals filed Critical Fovea Pharmaceuticals

2013-03-27 Publication of TN2011000379A1 publication Critical patent/TN2011000379A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Immunology (AREA)
Ophthalmology & Optometry (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

TN2011000379A 2009-02-13 2011-08-03 [1, 2, 4] triazolo [1,5-a ] pyridines as kinase inhibitors TN2011000379A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP09360013		2009-02-13
PCT/EP2010/051556 WO2010092041A1 (fr)	2009-02-13	2010-02-09	[1, 2, 4] triazolo [1, 5 -a] pyridines servant d'inhibiteurs de kinases

Publications (1)

Publication Number	Publication Date
TN2011000379A1 true TN2011000379A1 (en)	2013-03-27

Family

ID=42229029

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2011000379A TN2011000379A1 (en)	2009-02-13	2011-08-03	[1, 2, 4] triazolo [1,5-a ] pyridines as kinase inhibitors

Country Status (24)

Country	Link
US (1)	US20120041195A1 (fr)
EP (1)	EP2396324A1 (fr)
JP (1)	JP2012517971A (fr)
KR (1)	KR20110116160A (fr)
CN (1)	CN102317288A (fr)
AR (1)	AR075411A1 (fr)
BR (1)	BRPI1008850A2 (fr)
CA (1)	CA2751517A1 (fr)
CL (1)	CL2011001947A1 (fr)
CO (1)	CO6420343A2 (fr)
CR (1)	CR20110386A (fr)
DO (1)	DOP2011000248A (fr)
EA (1)	EA201101188A1 (fr)
EC (1)	ECSP11011250A (fr)
HN (1)	HN2011002095A (fr)
IL (1)	IL214426A0 (fr)
MX (1)	MX2011008549A (fr)
NI (1)	NI201100151A (fr)
NZ (1)	NZ594508A (fr)
PE (1)	PE20120110A1 (fr)
SG (1)	SG173610A1 (fr)
TN (1)	TN2011000379A1 (fr)
WO (1)	WO2010092041A1 (fr)
ZA (1)	ZA201105896B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI1009637A2 (pt)	2009-06-05	2019-04-30	Cephalon, Inc	composto, composição e uso de um composto
EP2343297A1 (fr) *	2009-11-30	2011-07-13	Bayer Schering Pharma AG	Triazolopyridines
EP2343295A1 (fr) *	2009-11-30	2011-07-13	Bayer Schering Pharma AG	Dérivés de triazolopyridine
EP2343294A1 (fr)	2009-11-30	2011-07-13	Bayer Schering Pharma AG	Triazolopyridines substituées
UY33452A (es) *	2010-06-16	2012-01-31	Bayer Schering Pharma Ag	Triazolopiridinas sustituidas
TW201204723A (en) *	2010-06-22	2012-02-01	Fovea Pharmaceuticals	Heterocyclic compounds, their preparation and their therapeutic application
JP5989091B2 (ja) *	2011-04-21	2016-09-07	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	トリアゾロピリジン類
WO2012160029A1 (fr)	2011-05-23	2012-11-29	Bayer Intellectual Property Gmbh	Triazolopyridines substituées
UA112096C2 (uk)	2011-12-12	2016-07-25	Байєр Інтеллектуал Проперті Гмбх	Заміщені триазолопіридини та їх застосування як інгібіторів ttk
KR20130091464A (ko)	2012-02-08	2013-08-19	한미약품 주식회사	타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체
JP6166289B2 (ja)	2012-03-14	2017-07-19	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	置換イミダゾピリダジン
EA027544B1 (ru)	2012-07-10	2017-08-31	Байер Фарма Акциенгезельшафт	Способ получения замещенных триазолопиридинов
WO2014020043A1 (fr)	2012-08-02	2014-02-06	Bayer Pharma Aktiengesellschaft	Combinaisons pour le traitement du cancer
HUE033131T2 (en)	2013-06-11	2017-11-28	Bayer Pharma AG	Derivatives of substituted triazolopyridines
US20230055321A1 (en) *	2019-11-22	2023-02-23	Medshine Discovery Inc.	Pyrimidopyrrole spiro compounds and derivatives thereof as dna-pk inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6056684B2 (ja)	1977-11-07	1985-12-11	東興薬品工業株式会社	点眼剤
US4271143A (en)	1978-01-25	1981-06-02	Alcon Laboratories, Inc.	Sustained release ophthalmic drug dosage
US4407792A (en)	1979-05-09	1983-10-04	Alcon Laboratories, Inc.	Sustained release ophthalmic drug dosage
JPH0830004B2 (ja)	1983-11-14	1996-03-27	コロンビアラボラトリーズインコーポレイテッド	生物接着性組成物およびそれにより治療する方法
US5041434A (en)	1991-08-17	1991-08-20	Virginia Lubkin	Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
EP1235815A1 (fr)	1999-11-22	2002-09-04	Warner-Lambert Company	Quinazolines et leur utilisation dans l'inhibition des enzymes kinase dependant de la cycline
US7268136B2 (en) *	2002-12-18	2007-09-11	Vertex Pharmaceuticals Incorporated	Compositions useful as inhibitors of protein kinases
BRPI0406809A (pt)	2003-01-17	2005-12-27	Warner Lambert Co	Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
CN1897950A (zh) *	2003-10-14	2007-01-17	惠氏公司	稠合芳基和杂芳基衍生物及其使用方法
CN1882345A (zh)	2003-10-16	2006-12-20	希龙公司	作为raf激酶抑制剂以治疗癌症的2,6－二取代的喹唑啉、喹喔啉、喹啉和异喹啉
NZ588139A (en)	2004-04-08	2012-02-24	Targegen Inc	7-Aryl-3-arylamino-benzo[1,2,4]triazine derivatives
EP1799656A4 (fr)	2004-08-25	2009-09-02	Targegen Inc	Composes heterocycliques et methodes d'utilisation
US20070054916A1 (en)	2004-10-01	2007-03-08	Amgen Inc.	Aryl nitrogen-containing bicyclic compounds and methods of use
AU2006227628A1 (en)	2005-03-16	2006-09-28	Targegen, Inc.	Pyrimidine compounds and methods of use
JP5079500B2 (ja)	2005-04-28	2012-11-21	協和発酵キリン株式会社	２−アミノキナゾリン誘導体
EP1893216A4 (fr)	2005-06-08	2012-08-08	Targegen Inc	Methodes et preparations pour le traitement de troubles oculaires
JP2009531274A (ja) *	2005-12-07	2009-09-03	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	キナーゼ阻害性ピロロピリジン化合物
PE20070978A1 (es)	2006-02-14	2007-11-15	Novartis Ag	COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
MX2009002171A (es) *	2006-08-30	2009-05-28	Cellzome Ltd	Derivados de triazol como inhibidores de cinasas.
CN101528744A (zh) *	2006-10-20	2009-09-09	Irm责任有限公司	用于调节c-kit和pdgfr受体的组合物和方法
TW200829566A (en)	2006-12-08	2008-07-16	Astrazeneca Ab	Chemical compounds
MX2009006627A (es)	2006-12-22	2009-08-12	Novartis Ag	Quinazolinas para la inhibicion de pdk1.
GB0719803D0 (en) *	2007-10-10	2007-11-21	Cancer Rec Tech Ltd	Therapeutic compounds and their use
PE20110063A1 (es) *	2008-06-20	2011-02-16	Genentech Inc	DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
CN102131389A (zh) *	2008-06-20	2011-07-20	健泰科生物技术公司	三唑并吡啶jak抑制剂化合物和方法
WO2010010188A1 (fr) *	2008-07-25	2010-01-28	Galapagos Nv	Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
WO2010010184A1 (fr) *	2008-07-25	2010-01-28	Galapagos Nv	[1, 2, 4]triazolo[1, 5-a]pyridines utilisées comme inhibiteurs de jak
WO2010010189A1 (fr) *	2008-07-25	2010-01-28	Galapagos Nv	Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
JP2011530483A (ja) *	2008-08-12	2011-12-22	武田薬品工業株式会社	アミド化合物
TWI453207B (zh) *	2008-09-08	2014-09-21	Signal Pharm Llc	胺基三唑并吡啶，其組合物及使用其之治療方法

2010
- 2010-02-09 SG SG2011057247A patent/SG173610A1/en unknown
- 2010-02-09 WO PCT/EP2010/051556 patent/WO2010092041A1/fr not_active Ceased
- 2010-02-09 CA CA2751517A patent/CA2751517A1/fr not_active Abandoned
- 2010-02-09 EP EP10706180A patent/EP2396324A1/fr not_active Withdrawn
- 2010-02-09 BR BRPI1008850A patent/BRPI1008850A2/pt not_active IP Right Cessation
- 2010-02-09 KR KR1020117018592A patent/KR20110116160A/ko not_active Withdrawn
- 2010-02-09 EA EA201101188A patent/EA201101188A1/ru unknown
- 2010-02-09 US US13/201,165 patent/US20120041195A1/en not_active Abandoned
- 2010-02-09 MX MX2011008549A patent/MX2011008549A/es not_active Application Discontinuation
- 2010-02-09 JP JP2011549537A patent/JP2012517971A/ja active Pending
- 2010-02-09 PE PE2011001470A patent/PE20120110A1/es not_active Application Discontinuation
- 2010-02-09 CN CN2010800077376A patent/CN102317288A/zh active Pending
- 2010-02-09 NZ NZ594508A patent/NZ594508A/en not_active IP Right Cessation
- 2010-02-12 AR ARP100100400A patent/AR075411A1/es not_active Application Discontinuation
2011
- 2011-07-15 CR CR20110386A patent/CR20110386A/es unknown
- 2011-07-28 NI NI201100151A patent/NI201100151A/es unknown
- 2011-07-29 HN HN2011002095A patent/HN2011002095A/es unknown
- 2011-07-29 DO DO2011000248A patent/DOP2011000248A/es unknown
- 2011-08-03 TN TN2011000379A patent/TN2011000379A1/fr unknown
- 2011-08-03 IL IL214426A patent/IL214426A0/en unknown
- 2011-08-09 EC EC2011011250A patent/ECSP11011250A/es unknown
- 2011-08-11 CO CO11102097A patent/CO6420343A2/es not_active Application Discontinuation
- 2011-08-11 CL CL2011001947A patent/CL2011001947A1/es unknown
- 2011-08-11 ZA ZA2011/05896A patent/ZA201105896B/en unknown

Also Published As

Publication number	Publication date
EP2396324A1 (fr)	2011-12-21
US20120041195A1 (en)	2012-02-16
WO2010092041A1 (fr)	2010-08-19
MX2011008549A (es)	2011-12-06
IL214426A0 (en)	2011-09-27
SG173610A1 (en)	2011-09-29
CO6420343A2 (es)	2012-04-16
EA201101188A1 (ru)	2012-04-30
HN2011002095A (es)	2014-01-06
CR20110386A (es)	2011-12-02
CN102317288A (zh)	2012-01-11
CA2751517A1 (fr)	2010-08-19
ZA201105896B (en)	2012-03-28
ECSP11011250A (es)	2011-10-31
NI201100151A (es)	2012-10-03
NZ594508A (en)	2013-12-20
DOP2011000248A (es)	2011-10-31
BRPI1008850A2 (pt)	2016-03-15
CL2011001947A1 (es)	2012-03-16
KR20110116160A (ko)	2011-10-25
JP2012517971A (ja)	2012-08-09
AR075411A1 (es)	2011-03-30
PE20120110A1 (es)	2012-02-20

Publication	Publication Date	Title
TN2011000379A1 (en)	2013-03-27	[1, 2, 4] triazolo [1,5-a ] pyridines as kinase inhibitors
TN2011000319A1 (en)	2012-12-17	Substituted quinazoline compounds
PH12015500988A1 (en)	2015-07-13	Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
PH12013501758A1 (en)	2013-10-14	Pyrazolo [1,5-a] pyridines as trk inhibitors
EA025281B9 (ru)	2017-08-31	СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ
WO2010005558A3 (fr)	2010-04-15	Inhibiteurs sélectifs des isoformes de la pi3 kinase
IN2014DN07384A (fr)	2015-04-24
NZ605022A (en)	2013-12-20	Heterocyclic compounds, their preparation and their therapeutic application
MX2014001239A (es)	2014-03-21	Compuestos de pirazolo [3,4-c] piridina y metodos de uso.
WO2013077921A3 (fr)	2013-10-03	Pyrazolo[3,4-d]pyrimidines substituées et utilisations de celles-ci
MX347917B (es)	2017-05-17	Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
AU2012277802A8 (en)	2014-03-06	Novel inhibitor compounds of phosphodiesterase type 10A
ZA201206715B (en)	2015-04-29	Imidazo [1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological,psychiatric and metabolic disorders and diseases
MY169268A (en)	2019-03-20	Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5-disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
MX2013011421A (es)	2013-12-09	Derivados de pirazolo-pirimidina.
MX2015000336A (es)	2015-04-14	Inhibidores de la enzima fosfodiesterasa 10.
WO2015165933A3 (fr)	2016-02-25	Imidazo[1,2-a]pyridine-carboxamides substitués en 6 et leur utilisation
MX2013006118A (es)	2013-12-16	Tratamiento de inflamacion cronica con un derivado de 1, 2, 4-triazolo [1,5a] piridina.
HK1189821A (en)	2014-06-20	Treatment of chronic inflammation with a 1,2,4-triazolo [1,5a] pyridine derivative
HK1197995A (en)	2015-03-06	Methods for treatment of incontinence associated with sexual activity